Acquisition Announced

Eli Lilly and Company acquisition of AttaiBeckley

US$3.8bn consideration

Announced 2026 (approx.)

Advisers

AttaiBeckley

Target

Financial adviser

Eli Lilly and Company

Acquirer

Not disclosed

Target
AttaiBeckley
Acquirer
Eli Lilly and Company
Target based in
Germany (unverified)
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development, Behavioral Health

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.